Robert Casey actually said...

"key among these challenges is reaching agreement with regulators about determining the appropriate efficacy endpoints to support approval of innovative medicines for rare diseases."

"We need creative ideas that can realign current market incentives to encourage drug developers to stay in this business."

"Mandatory stability standards would make our homes safer overall, but especially for children."

"I am proud to lead a bipartisan bill, the STURDY Act, alongside Senators Klobuchar, Blumenthal and Cotton."